(NEW YORK)German biotechnology company GPC Biotech AG said Friday its European partner withdrew an application for the troubled cancer drug candidate satraplatin, a move made by GPC in the U...READ MORE
(IRVINE, Calif.)Cancer drugs developer Spectrum Pharmaceuticals Inc. said Tuesday its first-quarter net loss widened as a result of increased research and development expenses.READ MORE
(WOODCLIFF LAKE, N.J.)Par Pharmaceutical Cos. said Wednesday it will pay Spectrum Pharmaceuticals Inc. $20 million in cash for its stake in a generic migraine injection. The payment will give Par 95 per...READ MORE
(NEW YORK)Spectrum Pharmaceuticals says its loss grew in 2007 because its research and development costs went up as it worked on its cancer drugs. The Irvine, Calif., company took a loss of ...READ MORE
(NEW YORK)Shares of Spectrum Pharmaceuticals Inc. surged in Monday premarket electronic trading, after the Food and Drug Administration late Friday approved its Levoleucovorin injectable dru...READ MORE
(NEW YORK)Shares of Spectrum Pharmaceuticals Inc. surged in Monday premarket electronic trading, after the Food and Drug Administration late Friday approved its Levoleucovorin injectable dru...READ MORE